Abstract
Plants have long been providing mankind with remedies of different ailments. Flavonoids, a family of naturally occurring polyphenolic compounds are ubiquitous in plants. Development of polyphenol-based drugs has not attracted much attention by researchers and drug companies. Therefore, despite extensive studies on polyphenols, this vast group of compounds is underrepresented in clinical medicine. Fisetin (3,7,3',4'-tetrahydroxyflavone) belongs to the flavonol subgroup of flavonoids together with quercetin, myricetin and kaempferol and is found in several fruits and vegetables including strawberries, apples, persimmons and onions. Fisetin is showing promise as a useful natural agent against cancer and has been evaluated for its potential inhibitory role against cancer in several in vitro and in vivo studies. The Akt/mTOR pathway is known to play a central role in various cellular processes that contribute to the malignant phenotype. Accordingly, inhibition of this signaling cascade has been a focus of recent therapeutic studies. Novel inhibitors of PI3-K, Akt, and mTOR are now passing through early phase clinical trials. Herein, we review the effect of fisetin on the PI3- K/Akt/mTOR pathway as studied in different cancer cell models.
Keywords: Fisetin, Akt, mTOR, lung cancer, prostate cancer, colon cancer, myeloma, melanoma.
Anti-Cancer Agents in Medicinal Chemistry
Title:Inhibition of Akt/mTOR Signaling by the Dietary Flavonoid Fisetin
Volume: 13 Issue: 7
Author(s): Deeba N. Syed, Vaqar M. Adhami, Mohammad Imran Khan and Hasan Mukhtar
Affiliation:
Keywords: Fisetin, Akt, mTOR, lung cancer, prostate cancer, colon cancer, myeloma, melanoma.
Abstract: Plants have long been providing mankind with remedies of different ailments. Flavonoids, a family of naturally occurring polyphenolic compounds are ubiquitous in plants. Development of polyphenol-based drugs has not attracted much attention by researchers and drug companies. Therefore, despite extensive studies on polyphenols, this vast group of compounds is underrepresented in clinical medicine. Fisetin (3,7,3',4'-tetrahydroxyflavone) belongs to the flavonol subgroup of flavonoids together with quercetin, myricetin and kaempferol and is found in several fruits and vegetables including strawberries, apples, persimmons and onions. Fisetin is showing promise as a useful natural agent against cancer and has been evaluated for its potential inhibitory role against cancer in several in vitro and in vivo studies. The Akt/mTOR pathway is known to play a central role in various cellular processes that contribute to the malignant phenotype. Accordingly, inhibition of this signaling cascade has been a focus of recent therapeutic studies. Novel inhibitors of PI3-K, Akt, and mTOR are now passing through early phase clinical trials. Herein, we review the effect of fisetin on the PI3- K/Akt/mTOR pathway as studied in different cancer cell models.
Export Options
About this article
Cite this article as:
Syed N. Deeba, Adhami M. Vaqar, Khan Imran Mohammad and Mukhtar Hasan, Inhibition of Akt/mTOR Signaling by the Dietary Flavonoid Fisetin, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (7) . https://dx.doi.org/10.2174/18715206113139990129
DOI https://dx.doi.org/10.2174/18715206113139990129 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Rho Kinase and Angiogenesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) P-gp Inhibition-Based Strategies for Modulating Pharmacokinetics of Anticancer Drugs: An Update
Current Drug Metabolism Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals Caspase-Independent Pathways of Programmed Cell Death: The Unraveling of New Targets of Cancer Therapy?
Current Cancer Drug Targets Recent Developments in Anti-Cancer Agents Targeting the Ras/Raf/ MEK/ERK Pathway
Recent Patents on Anti-Cancer Drug Discovery Development of a PBPK Model for Monoclonal Antibodies and Simulation of Human and Mice PBPK of a Radiolabelled Monoclonal Antibody
Current Pharmaceutical Design Functional Foods: Salient Features and Clinical Applications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Role of Class II Nuclear Receptors in Liver Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Design, Synthesis, and Docking Studies of 4H-Chromene and Chromene Based Azo Chromophores: A Novel Series of Potent Antimicrobial and Anticancer Agents
Current Organic Synthesis Molecular Pathways of Interferon-Stimulated Gene 15: Implications in Cancer
Current Protein & Peptide Science Neuropharmacology of the Endocannabinoid Signaling System-Molecular Mechanisms, Biological Actions and Synaptic Plasticity
Current Neuropharmacology Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Current Protein & Peptide Science Risk Factors for Postembolization Syndrome After Transcatheter Arterial Chemoembolization
Current Medical Imaging Cancer Cell Reprogramming: Stem Cell Differentiation Stage Factors and An Agent Based Model to Optimize Cancer Treatment
Current Pharmaceutical Biotechnology Bioactivity of Turmeric-derived Curcuminoids and Related Metabolites in Breast Cancer
Current Pharmaceutical Design Micro-CT Assessments of Potential Anti-Osteoporotic Agents
Current Drug Targets Large Scale Preparation of the Mammalian High Mobility Group Protein A2 for Biophysical Studies
Protein & Peptide Letters Decoding the Knots of Initiation of Oncogenic Epithelial-Mesenchymal Transition in Tumor Progression
Current Cancer Drug Targets High Expression of miR-206 Predicts Adverse Outcomes: A Potential Therapeutic Target for Esophageal Cancer
Combinatorial Chemistry & High Throughput Screening Interconnection of Estrogen/Testosterone Metabolism and Mevalonate Pathway in Breast and Prostate Cancers
Current Molecular Pharmacology